A Cancer Vaccine (Labvax 3(22)-23) and GM-CSF Alone or in Combination With Pembrolizumab for the Treatment of Advanced Stage Adenocarcinoma
Phase 1/2
77
about 8.2 years
18+
1 site in CA
About this study
This trial is testing a cancer vaccine called Labvax 3(22)-23, along with GM-CSF alone or combined with pembrolizumab, to treat adenocarcinoma that has spread. The goal is to see if this treatment can help the body's immune system fight against the cancer cells.
Based on ClinicalTrials.gov records.
What participants do
- 1.Receive Antineoplastic Vaccine
- 2.Receive Pembrolizumab
- 3.Receive Sargramostim
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
vaccine, pembrolizumab (Immune checkpoint inhibitor; blocks PD-1 to boost T-cell attack on cancer), sargramostim
injection, infusion
Primary: Phase 1: Adverse events (AEs), Phase 1: Dose-limiting toxicities (DLT), Phase 2: Objective response rate (ORR)
Secondary: Phase 1: Objective response rate (ORR), Phase 2: Adverse events (AEs), Phase 2: Dose-limiting toxicities (DLT), Phase 2: Overall survival (OS), Phase 2: Progression free survival (PFS)
Oncology